---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092270"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:51:58.465152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027

## Summary
- Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.
- Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).
- R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.
- Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.
- PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-092270
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/0000950170-24-092270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017024092270/tngx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092270
- JSON: https://secwatch.observer/filing/0000950170-24-092270.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.